Skip to main content
AAN.com
ARTICLES
August 1, 1996

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease
A review of 17 epidemiologic studies

August 1996 issue
47 (2) 425-432

Abstract

Alzheimer's disease (AD) lesions are characterized by the presence of numerous inflammatory proteins.This has led to the hypothesis that brain inflammation is a cause of neuronal injury in AD and that anti-inflammatory drugs may act as protective agents. Seventeen epidemiologic studies from nine different countries have now been published in which arthritis, a major indication for the use of anti-inflammatory drugs, or anti-inflammatory drugs themselves have been considered as risk factors for AD. Both factors appear to be associated with a reduced prevalence of AD. The small size of most studies has limited their individual statistical significance, but similarities in design have made it possible to evaluate combined results. We have used established methods of statistical meta-analysis to estimate the overall chance of individuals exposed to arthritis or anti-inflammatory drugs developing AD as compared with the general population. Seven case-control studies with arthritis as the risk factor yielded an overall odds ratio of 0.556 (p < 0.0001), while four case-control studies with steroids yielded odds ratios of 0.656 (p = 0.049) and three case-control studies with nonsteroidal anti-inflammatory drugs (NSAIDs) yielded an odds ratio of 0.496 (p = 0.0002). When NSAIDs and steroids were combined into a single category of anti-inflammatory drugs, the odds ratio was 0.556 (p < 0.0001). Population-based studies were less similar in design than case-control studies, complicating the process of applying statistical meta-analytical techniques. Nevertheless, population-based studies with rheumatoid arthritis and NSAID use as risk factors strongly supported the results of case-control studies. These data suggest anti-inflammatory drugs may have a protective effect against AD. Controlled clinical trials will be necessary to test this possibility.
NEUROLOGY 1996;47: 425-432

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
McGeer PL, Rogers J, McGeer EG. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8:149-165.
2.
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
3.
McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42:447-449.
4.
McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037.
5.
Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-341.
6.
French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer's type. Am J Epidemiol 1985;121:414-421.
7.
Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-1707.
8.
Breteler MMB, van Duijn CM, Andra VCI, et al. Medical history and the risk of Alzheimer's disease: a collaborative reanalysis of case-control studies. Int J Epidemiol 1991;20:S36-S42.
9.
Li G, Shen YC, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 1992;42:1481-1482.
10.
Anon. Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
11.
Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 1994;44:227-232.
12.
Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16;523-530.
13.
Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
14.
Jenkinson MI, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-87.
15.
Beard CM, Kokmen E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991;337:1426.
16.
Myllykangas-Luosujarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994;33:501-502.
17.
Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
18.
Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
19.
Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
20.
McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 1992;3:146-149.
21.
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981;160-176.
22.
Fleiss JL. Measures of effect size for categorical data. In: Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994;245-260.
23.
Shadish WR, Haddock CK. Combining estimates of effect size. In: Cooper H, Hedges LV, eds. The handbook of research synthesis, New York; Russell Sage Foundation, 1994:261-281.
24.
Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, 1985:107-145, 189-203, 285-309.
25.
Rosenthal R. The ``file drawer'' problem and tolerance for null results. Psychol Bull 1979;86:638-641.
26.
Begg CB. Publication bias. In: Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994;399-409.
27.
Anon. Canadian Study of Health and Aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
28.
Corrada M, Stewart W, Kawas C. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. Neurology 1996;46:A433.
29.
Landfield PW, Eldridge JC. Increased affinity of type II corticosteroid binding in aged rat hippocampus. Exp Neurol 1989;106:110-113.
30.
Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. J Affect Disord 1983;5:319-332.
31.
Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-1280.
32.
Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315.
33.
Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologia 1986;172:214-217.
34.
Boesen P, Dideriksen K, Stenoft J, Jensen MK. Dapsone in temporal arteritis and polymyalgia rheumatica. J Rheumatol 1988;15:879-880.
35.
Sharquie KE. Suppression of Behcet's disease with dapsone. Br J Dermatol 1984;110:493-494.
36.
Guillebin L. Treatment of polyarteritis nodosa with dapsone. Scand J Rheumatol 1986;15:95-96.
37.
Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
38.
Mortimer JA, Ebbitt B, Jun S-P, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.

Information & Authors

Information

Published In

Neurology®
Volume 47Number 2August 1996
Pages: 425-432
PubMed: 8757015

Publication History

Published online: August 1, 1996
Published in print: August 1996

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Patrick L. McGeer, PhD, FRCP(C), MD
From the Kinsmen Laboratory of Neurological Research, Department of Psychiatry (Drs McGeer and E.G. McGeer) and the Departments of Medicine and Statistics (Dr. Schulzer), University of British Columbia, Vancouver, BC, Canada.
Supported by grants from the Alzheimer Society of B.C. and the Jack Brown and Family A.D. Research Fund, as well as donations from individual British Columbians.
Received November 3, 1995. Accepted in final form January 19, 1996.
Address correspondence and reprint requests to Dr. Patrick L. McGeer, Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer’s Disease, Journal of Clinical Medicine, 14, 2, (331), (2025).https://doi.org/10.3390/jcm14020331
    Crossref
  2. Role of Nonsteroidal Anti-Inflammatory Drugs as a Protective Factor in Alzheimer’s Disease: A Systematic Review and Meta-Analysis, Neurology India, 72, 6, (1144-1151), (2024).https://doi.org/10.4103/ni.ni_1073_22
    Crossref
  3. Synthesis and Evaluation of Chloride-Substituted Ramalin Derivatives for Alzheimer’s Disease Treatment, Molecules, 29, 15, (3701), (2024).https://doi.org/10.3390/molecules29153701
    Crossref
  4. Aspects of Histopathological and Ultrastructural Retinal Changes in Chronic Exposure to Hydroxychloroquine, Medicina, 60, 6, (846), (2024).https://doi.org/10.3390/medicina60060846
    Crossref
  5. Medication Exposure and Risk of Dementia and Alzheimer’s Disease, International Journal of Molecular Sciences, 25, 23, (12850), (2024).https://doi.org/10.3390/ijms252312850
    Crossref
  6. Alzheimer’s disease and its treatment–yesterday, today, and tomorrow, Frontiers in Pharmacology, 15, (2024).https://doi.org/10.3389/fphar.2024.1399121
    Crossref
  7. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis, RMD Open, 10, 1, (e004016), (2024).https://doi.org/10.1136/rmdopen-2023-004016
    Crossref
  8. Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases, Ageing Research Reviews, 98, (102321), (2024).https://doi.org/10.1016/j.arr.2024.102321
    Crossref
  9. Neuroinflammation in Alzheimer's disease, Alzheimer's Disease and Advanced Drug Delivery Strategies, (13-32), (2024).https://doi.org/10.1016/B978-0-443-13205-6.00003-0
    Crossref
  10. Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies, Drugs & Aging, 41, 5, (423-430), (2024).https://doi.org/10.1007/s40266-024-01112-1
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share